Novartis | NVS | Long at $99.00As one of the largest pharmaceutical companies in the world, Novartis NYSE:NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
5.54 EUR
11.19 B EUR
47.13 B EUR
1.69 B
About NOVARTIS N
Sector
Industry
CEO
Vasant Narasimhan
Website
Headquarters
Basel
Founded
1996
ISIN
CH0012005267
FIGI
BBG000P33R75
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
NVS 1H Swing Long Conservative Trend TradeConservative Trend Trade
+ long impulse
+ 1/2 correction
+ T2 level
+ support level
- biggest volume 2Sp-
Calculated affordable stop limit
1 to 2 R/R within 1H range take profit
Daily Trend
"+ long impulse
+ 1/2 correction
+ JOC level
+ support level
- above 1/2 of entire 1D wave at the support le
Investing in Health: Reasons Why Novartis AG Stock Stands OutIn an era where health is wealth, and the global healthcare sector is booming like never before, savvy investors are looking for opportunities that promise growth and a meaningful impact on people’s lives. Enter Novartis AG—a powerhouse in pharmaceuticals that’s not only redefining treatments but al
NVS Novartis AG Options Ahead of EarningsAnalyzing the options chain and the chart patterns of NVS Novartis AG prior to the earnings report this week,
I would consider purchasing the 110usd strike price Calls with
an expiration date of 2024-8-16,
for a premium of approximately $3.30.
If these options prove to be profitable prior to the ear
Novartis Strikes $1.01 Bln Deal with Arvinas for Prostate DrugsNovartis ( NYSE:NVS ), the Swiss pharmaceutical giant, has made a strategic move in the field of cancer treatment by securing a licensing agreement with Arvinas, a U.S. biotech company. The deal, valued at up to $1.01 billion, grants Novartis access to Arvinas' experimental prostate cancer drug, ARV
Investment Opportunity Novartis AG (short)Wyckoff in Daily/Weekly timeframe, we can observe the price took the upside liquidity (bc) before breaking the structure downside.
I'm expecting the price to go back on my grey zone (supply) around 99 before continuing the bearish trend.
First target 88 (sc)
Second target 83 (demand zone)
I will l
Longing Novartis (NVS) Longing Novartis (NVS): A Strategic Investment Amidst Geopolitical Tensions
This article presents a compelling rationale for considering a long position in Novartis (NVS) stock. The primary driving factor behind this investment strategy is Novartis' close association with Sandoz (SDZ) following the
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US66989HAS7
NOVARTIS CAP 20/50Yield to maturity
6.83%
Maturity date
Aug 14, 2050
NVS3904288
Novartis Capital Corp. 3.7% 21-SEP-2042Yield to maturity
6.13%
Maturity date
Sep 21, 2042
XPND
NOVARTIS CAPITAL 15/45Yield to maturity
6.12%
Maturity date
Nov 20, 2045
US66989HAH1
NOVARTIS CAPITAL 14/44Yield to maturity
5.96%
Maturity date
May 6, 2044
NVS5894401
Novartis Capital Corp. 4.7% 18-SEP-2054Yield to maturity
5.91%
Maturity date
Sep 18, 2054
NVS5894400
Novartis Capital Corp. 4.2% 18-SEP-2034Yield to maturity
5.17%
Maturity date
Sep 18, 2034
US66989HAR9
NOVARTIS CAP 20/30Yield to maturity
4.74%
Maturity date
Aug 14, 2030
NVS5894399
Novartis Capital Corp. 4.0% 18-SEP-2031Yield to maturity
4.65%
Maturity date
Sep 18, 2031
XPNC
NOVARTIS CAPITAL 15/25Yield to maturity
4.55%
Maturity date
Nov 20, 2025
NVS5894398
Novartis Capital Corp. 3.8% 18-SEP-2029Yield to maturity
4.40%
Maturity date
Sep 18, 2029
US66989HAN8
NOVARTIS CAPITAL 17/27Yield to maturity
4.24%
Maturity date
May 17, 2027
See all NOT bonds
Curated watchlists where NOT is featured.
Related stocks
Frequently Asked Questions
The current price of NOT is 95.97 EUR — it has decreased by −3.68% in the past 24 hours. Watch NOVARTIS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange NOVARTIS INC stocks are traded under the ticker NOT.
We've gathered analysts' opinions on NOVARTIS INC future price: according to them, NOT price has a max estimate of 129.19 EUR and a min estimate of 78.77 EUR. Watch NOT chart and read a more detailed NOVARTIS INC stock forecast: see what analysts think of NOVARTIS INC and suggest that you do with its stocks.
NOT stock is 5.81% volatile and has beta coefficient of 0.93. Track NOVARTIS INC stock price on the chart and check out the list of the most volatile stocks — is NOVARTIS INC there?
Today NOVARTIS INC has the market capitalization of 184.81 B, it has decreased by −0.51% over the last week.
Yes, you can track NOVARTIS INC financials in yearly and quarterly reports right on TradingView.
NOVARTIS INC is going to release the next earnings report on Apr 29, 2025. Keep track of upcoming events with our Earnings Calendar.
NOT earnings for the last quarter are 1.91 EUR per share, whereas the estimation was 1.74 EUR resulting in a 9.72% surprise. The estimated earnings for the next quarter are 1.95 EUR per share. See more details about NOVARTIS INC earnings.
NOVARTIS INC revenue for the last quarter amounts to 12.71 B EUR, despite the estimated figure of 12.40 B EUR. In the next quarter, revenue is expected to reach 12.09 B EUR.
NOT net income for the last quarter is 2.63 B EUR, while the quarter before that showed 2.93 B EUR of net income which accounts for −10.20% change. Track more NOVARTIS INC financial stats to get the full picture.
Yes, NOT dividends are paid annually. The last dividend per share was 3.63 EUR. As of today, Dividend Yield (TTM)% is 3.86%. Tracking NOVARTIS INC dividends might help you take more informed decisions.
NOVARTIS INC dividend yield was 3.95% in 2024, and payout ratio reached 67.17%. The year before the numbers were 3.89% and 51.36% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 21, 2025, the company has 75.88 K employees. See our rating of the largest employees — is NOVARTIS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVARTIS INC EBITDA is 20.10 B EUR, and current EBITDA margin is 42.40%. See more stats in NOVARTIS INC financial statements.
Like other stocks, NOT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVARTIS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVARTIS INC technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVARTIS INC stock shows the strong buy signal. See more of NOVARTIS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.